These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894 [No Abstract] [Full Text] [Related]
8. Molecule of the month. Sorafenib. Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266 [No Abstract] [Full Text] [Related]
10. Highlights from the Eigth International Kidney Cancer Symposium. Hutson T Clin Adv Hematol Oncol; 2009 Dec; 7(12):796-8. PubMed ID: 20332749 [No Abstract] [Full Text] [Related]
11. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eng FC; Easson AM; Szentgyorgyi E; Knox JJ Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949 [No Abstract] [Full Text] [Related]
12. Evidence-based urology in practice: when to believe a subgroup analysis? Wang SS; Ou YC; Cheng CL; Dahm P; BJU Int; 2010 Jan; 105(2):162-4. PubMed ID: 19912181 [No Abstract] [Full Text] [Related]
13. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma]. Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165 [No Abstract] [Full Text] [Related]
14. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424 [TBL] [Abstract][Full Text] [Related]
15. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541 [TBL] [Abstract][Full Text] [Related]
16. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Bellmunt J; Fishman M; Eisen T; Quinn D Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma. Kuzuya T; Tsuchiya K; Izumi N Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944 [No Abstract] [Full Text] [Related]
19. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community. Bukowski RM Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842 [TBL] [Abstract][Full Text] [Related]
20. Hand-foot and stump syndrome to sorafenib. Lai SE; Kuzel T; Lacouture ME J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051 [No Abstract] [Full Text] [Related] [Next] [New Search]